Carcinoid tumors that Of. Stage 4 M March lymphopenia in 70% of patients with 10% of opportunistic infections, a known side Etoposide Topoisomerase inhibitor effect of temozolomide was noted. A retrospective study showed that temozolomide was approximately 14% of patients w During an active phase II trial of thalidomide in 18 patients with NET showed no antitumor activity t. These results suggest that the active ingredient in this combination is likely to temozolomide. However, it is difficult to know whether there was a significant difference between the activity t of temozolomide and dacarbazine, because no studies comparing these two agents. Recently, the combination of temozolomide and capecitabine has been studied in a retrospective study of patients within Pannet front-line treatment. The overall response rate was 70%, as measured by RECIST criteria, with a median progression-free survival time of 18 months.
PCP prophylaxis is again given the lymphopenia as in the studies reported recommended described above. Platinum-based therapies have promising activity of t shown in small phase II trials Pannet. A study of gemcitabine and oxaliplatin have reported a response rate of 17% and processing time of 7 months. Similar to a study of capecitabine plus oxaliplatin reported a response rate of 27% in 11 panNETs Duration of response was approximately 1 year. More recently, two reports were from the area of San Francisco, a T ACTION with fluorouracil, oxaliplatin, the combination of bevacizumab. The first report Bergland et al. reported a response rate of 50% in 12 patients who again u Pannet progressive short-term infusion of 5-fluorouracil, Folin more acid and bevacizumab. The second report by Kunz et al. Capecitabine in combination with oxaliplatin and bevacizumab for four treatments and reported a response rate of 19%. Cytotoxic chemotherapy for carcinoid tumors Dependence Dependence of the reactivity of t on the deficit of temozolomide Re MGMT expression may be explained Ren, the lack of benefit of this drug in some NET and carcinoembryonic Of particular. Kulke et al. retrospectively 76 patients, the treatment temozolomidebased.
A radiological remission was observed in approximately 33% of patients with pancreatic NET, but at 0% of patients with carcinoid tumors Of. Erh Available in 21 samples, a total lack of expression of methyl guanine methyltransferase seems patients with pancreatic NETwho considerable advantages of temozolomide achieve defined. The r Was on streptozocin, 5-fluorouracil or cyclophosphamide carcinoembryonic tested in an ECOG study of 118 patients Of metastatic carcinoid tumors Cladribine 4291-63-8 Of criteria with the help of very old Including Lich k Rperliche tests for response, response rates for both arms were Similar, with no difference in overall survival, however, significant toxicity t, occurred as nausea and renal Sch Accusations that were as unacceptable. A follow-up study at lower doses of streptozocin plus 5-FU with doxorubicin alone showed no difference in overall survival. A four-drug combination of 5-FU, doxorubicin, cyclophosphamide, and streptozocin in 56 patients with carcinoid tumors Advances had a median overall survival of 11 months only. Closing Lich is a Phase II-III ECOG study of 250 patients re Oivent of doxorubicin plus 5-FU with 5-FU, streptozocin in the treatment of advanced Carcin compared.